Among them, the ALK+ ALCL have a defining translocation featured by fusion of ALK, most commonly with NPM1 (85%), which have a significantly better outcome (70% to 90% 5-year OS) than ALK− ALCL (15% to 58%) [52, 53]. The gene discussed is ALK; the disease is anaplastic large cell lymphoma.